Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK



9307

Accredited to ISO 15189:2022

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Bristol Genetics Laboratory Pathology Sciences Building Southmead Hospital Westbury on Trym

BS10 5NB

Contact: Laura Johnston Tel: +44 (0)117 414 6168

E-Mail: Laura.Johnston@nbt.nhs.uk Website: www.nbt.nhs.uk/severn-

pathology/pathology-services/bristol-genetics-

laboratory-bgl

Testing performed at the above address only

DETAIL OF ACCREDITATION

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	
HUMAN TISSUE AND FLUIDS	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer	Documented in house procedures incorporating manufacturer's instructions (where relevant):	
	DNA/RNA Extraction, quantification and quality check for subsequent in-house analysis (see below), referral to specialist centres and long- term storage	Manual semi-automated and automated DNA /RNA extraction and quantification using: DNA Extraction :	
Tissue, CVS, Saliva, Cultured cells		Manual extraction processes 17.6.28, 21.26, 17.6.32,	
Peripheral Blood, PET, Prenatal		Qiagen Qiacube 17.6.33, 17.6.24, 17.6.36	
Peripheral Blood		Promega Tecan Freedom Evo 17.6.35	
Peripheral Blood and Bone Marrow		QIAsymphony using QIAsymphony DSP DNA Mini and Midi kit 17.6.37	
Peripheral Blood, Prenatal, Bone Marrow, FFPE and Blood Spot		EZ1 Biorobot 17.6.27	
Solid tumour and tissue		Automated extraction processes QIAsymphony 17.6.41	
FFPE		Promega Maxwell RSC 48 instrument and Maxwell RSC DNA/RNA FFPE Kit (DNA and RNA) and in-house method SOP 17.6.42	
Plasma		ccfDNA extraction Manual extraction processes QIAmp Circulating Nucleic Acid Kit QIAvac 24 Plus vacuum manifold 17.6.39	

Assessment Manager: AK3 Page 1 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
	DNA/RNA Extraction, quantification and quality check for subsequent in-house analysis (see below), referral to specialist centres and long- term storage (cont'd)	Manual, semi-automated and automated DNA /RNA extraction and quantification using:
Plasma		DNA Quantification for QC purposes: Nanodrop ND2000 and ND8000 17.6.8 Qubit 4.0 and Qubit Flex 17.55.5
FFPE		RNA extraction: Manual process and automated using Qiacube 17.6.34
Peripheral Blood		Automated using Qiacube 20.12
Whole Blood, FFPE		Promega Maxwell RSC 48 instrument and Maxwell RSC simplyRNA Blood Kit (SOP 17.2.43) and Maxwell RSC DNA/RNA FFPE Kit (SOP 17.6.42)
		RNA Quantification for QC purposes: Nanodrop ND2000 and ND8000, 17.6.8 Qubit 4.0 and Qubit Flex 17.55.5
Genomic DNA & RNA extracted in house from the sample types listed above and received as primary samples from external sources	Detection of nucleic acid sequence variant - SNVs and Indels [Definitive list in APP15/60]	Sanger Sequencing Using: Standard primer design methodology, PCR amplification, gel electrophoresis Beckman Coulter NXp/FxP robots and Thermocyclers. Sanger Sequencing performed using Applied Biosystems ABI 3730 DNA analyser and Mutation Surveyor software 17.23.8, MRD/S3/003, 18.1, 17.23.5

Assessment Manager: AK3 Page 2 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

	Type of test/Properties	
Materials/Products tested	measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
Genomic DNA extracted in house from the sample types listed above and received as primary samples from external sources (cont'd)	Detection of nucleic acid sequence variants, small indels and/or determination of methylation status [Definitive list in APP15/60]	Pyrosequencing Using: Qiagen Pyromark Q48Pyrosequencer PCR amplification using kits electrophoresis, Beckman Coulter NXp/FxP robots and Thermocyclers. BGL/TECH/PYRO/SOP/1
Genomic DNA and RNA extracted in house from the sample types listed above and received as primary samples from external sources (cont'd)	Qualitative Genotype analysis for SNVs, indels and fusion transcripts [Definitive list in APP15/60]	Qualitative Real Time PCR Using: Life Technologies 7500 and 7500 FAST real time analysers and Quantstudio 5 analysers and: 17.23.12, 17.43.3, 20.27 BGL/TECH/REAL-TIME/SOP/1
Whole Blood	Genotyping DPYD	Genotyping using Loop-mediated isothermal Amplification (LAMP) Melt Analysis (LaCar) (Qualitative PCR) using Quantstudio 5 Manual or Automated Set Up using BioMek NxP liquid hander or FXP liquid handler BGL/TECH/REAL-TIME/SOP/2 Analysis using BGL/TECH/NGS/SOP/3
RNA extracted from peripheral blood and bone marrow (see above)	Generation of cDNA by reverse transcriptase for subsequent in-house analysis (see below)	cDNA generation: Manual method using Applied Biosystems cDNA Reverse Transcription Kit
		17.6.38
RNA extracted in house from the sample types listed above and received as primary samples from external sources (cont'd)	For the qualitative detection of common fusion transcripts associated with malignancy [Definitive list in APP15/60]	Qualitative Reverse Transcriptase PCR (RTPCR) Using: G Storm Thermocycler and gel electrophoresis and Genesnap visualisation and: 20.13

Assessment Manager: AK3 Page 3 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

	Type of test/Properties	Standard specifications/ Equipment/Techniques
Materials/Products tested	measured/Range of measurement	used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
Genomic DNA and RNA extracted in house from the sample types listed above and received as primary samples from external sources (cont'd)	Quantitative analysis of known gene fusions events for the monitoring of malignancies [Definitive list in APP15/60]	Quantitative Real Time PCR Using: Life Technologies 7500 and 7500 FAST real time analysers and Quantstudio 5 analysers and: 20.15: (RQ-PCR for BCR-ABL transcripts) MRD/S2/003, MRD/S4/003, MRD/S5/001
	Gene screening of large gene panels for genetic variants [Definitive list in APP15/60]	Next Generation Sequencing:
	SNVs	Library Preparation methods: Nextera Flex with Twist Biosciences Illumina TSO500 Illumina Trusight TST15
	CNVs	Nextera Flex with Twist Biosciences probe set
	Indels	Nextera Flex with Twist Biosciences probe set Illumina Trusight TST15 Illumina TSO500
	IDT	Illumina TSO500
	Gene Screening Gene rearrangements at the immunoglobulin and T cell receptor loci for minimal residual disease (MRD)	Library Preparation Amplicon based MRD 17.55.24
	SNP genotyping for identity checks for NGS for WGS	Library Preparation Amplicon based

Assessment Manager: AK3 Page 4 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
Genomic DNA and RNA extracted in house from the sample types listed and samples received as primary samples from external sources (cont'd)	Gene screening of large gene panels for genetic variants [Definitive list in APP15/60]	Next Generation Sequencing: Using: Agilent 2200 and 4200 Tapestation, Qubit 2.0, 4.0 and Qubit Flex Fluorometer, thermal cycler and Beckman Biomek i7 Hybrid liquid handling robot and Illumina MiSeq and/or NextSeq or NovaSeq 6000 17.55.4, 17.55.5, 17.55.6, 17.55.21, 17.55.22, Covaris LE220R (only TSO500 on DNA extracted from FFPE) BGL/TECH/NGS/SOP/1 BGL/TECH/NGS/SOP/2 BGL/TECH/NGS/SOP/6 BGL/TECH/NGS/SOP/8 Analysis using: Clinical Exome and targeted panel pipeline 25.2 Somatic VariantsBGL/Analysis/SOP/1 BGL/SOLIDTUMOUR/SOP/1 MRD NGS pipeline 25.9 DNA nexus somatic pipelines (SOP 25.10) SNP genotyping pipeline BGL/TECH/NGS/SOP/3
Genomic DNA extracted in house from peripheral blood, bone marrow trephine or fresh tissue	SNP array for Oncology	Qubit 4.0 and Qubit Flex Fluorometer, NextSeq550 array scanner and Infinium CytoSNP-850K v1.2 BeadChip Assay 17.55.5 BGL/TECH/ARRAY/SNP MICROARRAY/SOP/1 Analysis using: BGL/ANALYSIS/SOP/2

Assessment Manager: AK3 Page 5 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
Genomic DNA extracted in house from the sample types listed and samples received as primary samples from external sources. Unless otherwise stated testing is undertaken on DNA.	Detection of fragment length size, deletions, known mutations, repeat expansions, linkage markers. [Definitive list in APP15/60]	Fragment length analysis Nucleic acid amplification Using: G Storm thermocyclers (GS0004M) and Coulter CEQ8000 / ABI 3730 and 3500 Genetic Analysers using GeneMarker and Genemapper analysis software 17.23.25, 17.23.14, ,17.23.2,20.17, BGL/TECH/FRAG/SOP/3 17.4.1, 17.4.6, 17.7.9, 17.46.1,BGL/TECH/FRAG/SOP/1, BGL/TECH/FRAG/SOP/2, BGL/RD3/SOP/1
Genomic DNA extracted in house from the sample types listed and samples received as primary samples from external sources	Determination of copy number changes [Definitive list in APP15/60]	Multiplex Ligation Probe Amplification (MLPA) Using: G Storm thermocyclers, ABI 3730, Beckman CEQ8000 and GeneMarker and Coffalyser data analysis software 17.23.18, 12.55
Genomic DNA extracted in house from the sample types listed	Detection of large gene rearrangements [Definitive list in APP15/60]	Using: Model 400 and Carbolite Hybridisation incubators, Stratolinker and XO Graph, and Chemiluminescence detection 17.8.1
Genomic DNA extracted in house from peripheral blood, bone marrow and FFPE tissues	Detection of single nucleotide variants and small indels [Definitive list in APP15/60]	Droplet digital PCR Using: BioRAD QX200 Droplet Reader BioRAD AutoDroplet Generator BioRAD PCR Plate Reader and: BGL/TECH/ddPCR/SOP/1

Assessment Manager: AK3 Page 6 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

resumg performed at main addites only			
Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):	
Whole blood Amniotic fluid CVS Foetal Blood Products of conception Bone Marrow Whole Blood Tissues/Skin Biopsies Buccal cells	G-banding/Karyotyping: Detection of chromosomal rearrangements or aberrations arising from: (e.g.) Prenatally detected Disorders Developmental disorders Reproductive medicine disorders Haematological/Oncology disorders (preparative pre-examination steps listed first)	Culturing and processing of human tissue/cells to provide interphase cells: Automated process using StemCell Robosep fully automated cell separator using: SOP 3.30 And 2.5, 2.7, 2.8 (Prenatal) 3.4 (Constitutional – blood) 3.7, (Oncology) 3.30, 4.0, 4.6, 4.20 (Solid tissue) Cell Harvesting: Manual harvesting using 3.16, 3.28 Automated process using Genial Genetics Coverslip Harvester and: 2.12 Chromosome analysis Microscopic analysis of G banded chromosomes Carl Zeiss light microscope and Metasystems Image analysis suite and: 13.3, 10 and 10.2 7.1, 7.3, 7.5, 3.22, 4.13 Manual analysis using: 10, 10.2,7.4, 7.5, 7.7	

Assessment Manager: AK3 Page 7 of 8



Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

North Bristol NHS Trust

Issue No: 009 Issue date: 25 July 2024

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer (cont'd)	Documented in house procedures incorporating manufacturer's instructions (where relevant):
Genomic DNA extracted in house from the sample types listed above and received as primary samples from external sources	Cytogenetic examinations for diagnosing postnatal disorders prenatal diagnosis, neoplastic genetics including haemato-oncology and solid tumours loss of pregnancy by detection of submicroscopic chromosomal imbalance (gains and losses) expressed as changes to copy number	Array Comparative Genomic Hybridisation (aCGH) processing Competitive hybridisation of patient and control DNA using hybridisation oven, MiVac and Agilent array scanner and Scigene Little Dipper slide washer. Analysis and interpretation of genetic imbalances using Cytosure Interpret software 21.24 21.11
Formalin fixed paraffin embedded tissue (FFPE) Peripheral Blood Bone Marrow Fixed culture cells (more specific – cultured, uncultured PB, Marrow, AFs etc) Amniotic fluid CVS- Chorionic villus samples	Detection of chromosomal aberrations in the diagnosis of haematological malignancy, bone marrow failure syndromes, non-haematological malignancies and constitutional disorders, solid tumours and companion testing Break-apart probes Fusion products Deletion Insertion Copy Number / Amplification	Fluorescence in situ hybridisation (FISH) Fluorescent in situ hybridisation (FISH) using commercial and in house developed probes by Hybrite using: SOP0504, SOP0502, SOP0524 and analysis using Fluorescent microscope and Carl Zeiss Metasystems Image analysis suite. and: SOP13.3
END		

Assessment Manager: AK3 Page 8 of 8